Keyword: Dipexium Pharmaceuticals

Dipexium plummets on total PhIII failure

Dipexium Pharmaceuticals saw its shares fall by more than 80% premarket on the news that two of its Phase III programs missed the primary and secondary endpoints in diabetic foot infections.